Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.
January 2023 AbbVie Inc. Company Confidential
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.